

Darren Green, GSK, conference chair invitation to attend 3rd Annual AI in Drug Discovery Conference

SMi Report: Conference Chairman Darren Green from GSK personally invites you the 3rd Annual AI in Drug Discovery Conference taking place on 14 and 15 March 2022

LONDON, LONDON, UNITED KINGDOM, January 23, 2022 /EINPresswire.com/ -- [The conference](#) will have a focus on case studies from leading pharma and biotech firms, as well as a exploring the latest innovations in machine learning for enhancing discovery pipelines.

Darren Green, Director of Computational Chemistry at GSK will be chairing at the [two-day conference](#) which is sponsored by Optibrium.



Darren Green's chair invite letter can be downloaded on the conference website <http://www.ai-indrugdiscovery.com/PR3> in the 'download centre', and below is a snippet of the invitation.

"It is with great pleasure that I invite you to SMI's 3rd Annual AI in Drug Discovery Conference, taking place on the 14th – 15th March 2022 in London.

As part of SMI's leading series of Drug Discovery conferences, this year's event will showcase techniques and case studies from target discovery all the way through drug discovery to clinical trials and regulatory considerations.

As usual, the conference will highlight the latest developments and case studies in the use of AI within drug discovery, and this year we have extended our domain coverage to include innovations in clinical trials and patient-centric precision medicine.

In addition to the presentations from industry professionals, there will be an interactive panel discussion about the use of AI in drug discovery for the treatment of rare diseases.

[Key Reasons to Attend:](#)

- Discover the main topics of research within industry, with talks on decision making, target selection and closing the loop
- Engage with regulators about the guidance within machine learning and AI in Drug Discovery
- Learn about the new breakthroughs within clinical trials and the treatment of disease
- Explore the latest technologies in deep learning from leaders within the pharmaceutical industry.
- Discuss the impact of big data and how it applies to AI drug discovery within Pharma

Following the main event, 2 post-conference workshops will be held on Wednesday 16th March 2022. There will be the opportunity to discuss the use of AI through the process of drug discovery into the world of healthcare.”

If you wish to join the conference you can register your place by visiting <http://www.ai-indrugdiscovery.com/PR3>

Sponsored by Optibrium

Interested in sponsoring, exhibiting or speaking at this event? Contact Daniele Moreschi, Sales Director, on +44 (0) 20 827 6050 or email dmoreschi@smi-online.co.uk

For media enquiries or to enquire about a press pass, contact Simi Sapal, Head of Marketing on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMi's 3rd Annual AI in Drug Discovery Conference

Conference: 14 – 15 March 2022

London, UK

Website: <http://www.ai-indrugdiscovery.com/PR3>

#SMiAlinDrugDis

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

SMi Group

SMi Group
02078276162
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/561335063>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.